Sisyphus and translational stroke research

Science Translational Medicine

Volumn 4, Issue 156, 2012, Pages

  Lyden, Patrick ^a   Lapchak, Paul ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CD18 ANTIGEN; DISUFENTON SODIUM; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD18; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

BLOOD VESSEL CLIP; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; LOW LEVEL LASER THERAPY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; BIOLOGICAL ASSAY; BRAIN ISCHEMIA; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84867801757     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005083     Document Type: Review

References (30)

1. V. E. O'Collins, M. R. Macleod, G. A. Donnan, L. L. Horky, B. H. van der Worp, D. W. Howells, 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006).
2. D. J. Cook, L. Teves, M. Tymianski, A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci. Transl. Med. 4, 154ra133 (2012).
3. S. E. Karpiak, A. Tagliavia, C. G. Wakade, Animal models for the study of drugs in ischemic stroke. Annu. Rev. Pharmacol. Toxicol. 29, 403-414 (1989).
4. C. Y. Hsu, Criteria for valid preclinical trials using animal stroke models. Stroke 24, 633-636 (1993).
5. J. Grotta, Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J. Intern. Med. 237, 89-94 (1995).
6. J. De Keyser, G. Sulter, P. G. Luiten, Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci. 22, 535-540 (1999).
7. M. D. M. Hill, R. H. Martin, D. Mikulis, J. H. Wong, F. L. Silver, K. G. terBrugge, G. Milot, W. M. Clarke, R. L. MacDonald, M. E. Kelly, M. Boulton, I. Fleetwood, C. MacDougall, T. Gunnarsson, M. Chow, C. Lum, R. Dodd, J. Poublanc, T. Krings, A. M. Demchuk, M. Goyal, R. Anderson, J. Bishop, D. Garman, M. Tymianski, Safety and efficacy of NA-1 for neuroprotection in iatrogenic stroke after endovascular aneurysm repair: A randomized controlled trial. Lancet Neurol. (2012); 10.1016/S1474-4422(12)70225-9
8. S. Y. Sim, Y. S. Shin, Silent microembolism on diffusion-weighted MRI after coil embolization of cerebral aneurysms. Neurointervention 7, 77-84 (2012).
9. R. W. Kruis, F. A. Vlasveld, D. Van Dijk, The (un)importance of cerebral microemboli. Semin. Cardiothorac. Vasc. Anesth. 14, 111-118 (2010).
10. D. C. Tong, A. Bolger, G. W. Albers, Incidence of transcranial Doppler-detected cerebral microemboli in patients referred for echocardiography. Stroke 25, 2138-2141 (1994).
11. M. A. Ritter, R. Dittrich, N. Thoenissen, E. B. Ringelstein, D. G. Nabavi, Prevalence and prognostic impact of microembolic signals in arterial sources of embolism. A systematic review of the literature. J. Neurol. 255, 953-961 (2008).
12. C. H. Timaran, E. B. Rosero, A. E. Martinez, A. Ilarraza, J. G. Modrall, G. P. Clagett, Atherosclerotic plaque composition assessed by virtual histology intravascular ultrasound and cerebral embolization after carotid stenting. J. Vasc. Surg. 52, 1188-1194 (2010).
13. A. Madani, V. Beletsky, A. Tamayo, C. Munoz, J. D. Spence, High-risk asymptomatic carotid stenosis: Ulceration on 3D ultrasound vs TCD microemboli. Neurology 77, 744-750 (2011).
14. J. A. Zivin, M. Fisher, U. DeGirolami, C. C. Hemenway, J. A. Stashak, Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230, 1289-1292 (1985).
15. J. A. Zivin, D. R. Waud, Quantal bioassay and stroke. Stroke 23, 767-773 (1992).
16. P. D. Lyden, C. Jackson-Friedman, C. Shin, S. Hassid, Synergistic combinatorial stroke therapy: A quantal bioassay of a GABA agonist and a glutamate antagonist. Exp. Neurol. 163, 477-489 (2000).
17. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1588 (1995).
18. P. A. Lapchak, Translational stroke research using a rabbit embolic stroke model: A correlative analysis hypothesis for novel therapy development. Transl Stroke Res 1, 96-107 (2010).
19. W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Daválos, D. Guidetti, V. Larrue, K. R. Lees, Z. Medeghri, T. Machnig, D. Schneider, R. von Kummer, N. Wahlgren, D. Toni, ECASS Investigators, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317-1329 (2008).
20. P. A. Lapchak, J. Wei, J. A. Zivin, Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35, 1985-1988 (2004).
21. Y. Lampl, J. A. Zivin, M. Fisher, R. Lew, L. Welin, B. Dahlof, P. Borenstein, B. Andersson, J. Perez, C. Caparo, S. Ilic, U. Oron, Infrared laser therapy for ischemic stroke: A new treatment strategy: Results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38, 1843-1849 (2007).
22. J. A. Zivin, G. W. Albers, N. Bornstein, T. Chippendale, B. Dahlof, T. Devlin, M. Fisher, W. Hacke, W. Holt, S. Ilic, S. Kasner, R. Lew, M. Nash, J. Perez, M. Rymer, P. Schellinger, D. Schneider, S. Schwab, R. Veltkamp, M. Walker, J. Streeter, NeuroThera Effectiveness and Safety Trial-2 Investigators, Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40, 1359-1364 (2009).
23. Enlimomab Acute Stroke Trial Investigators, Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. Neurology 57, 1428-1434 (2001).
24. P. A. Lapchak, D. M. Araujo, D. Song, J. Wei, J. A. Zivin, Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino) methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Stroke 33, 1411-1415 (2002).
25. A. Shuaib, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, H. C. Diener, T. Ashwood, W. W. Wasiewski, U. Emeribe, SAINT II Trial Investigators, NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357, 562-571 (2007).
26. P. A. Lapchak, D. Song, J. Wei, J. A. Zivin, Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188, 279-285 (2004).
27. K. R. Lees, J. A. Zivin, T. Ashwood, A. Davalos, S. M. Davis, H. C. Diener, J. Grotta, P. Lyden, A. Shuaib, H. G. Hårdemark, W. W. Wasiewski, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators, NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588-600 (2006).
28. P. D. Lyden, B. C. Meyer, T. M. Hemmen, K. S. Rapp, An ethical hierarchy for decision making during medical emergencies. Ann. Neurol. 67, 434-440 (2010).
29. M. Fisher, G. Feuerstein, D. W. Howells, P. D. Hurn, T. A. Kent, S. I. Savitz, E. H. Lo, STAIR Group, Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250 (2009).
30. Sisyphus, Titian; http://www.wikipaintings.org/en/search/ titian%20sisyphus/1#supersized-search-225013. The author of this artwork died more than 70 years ago. According to U.S. Copyright Law, copyright expires 70 years after the author's death.